风疹特异性中和抗体滴度的高通量检测优化及统计插值法
High-throughput assay optimization and statistical interpolation of rubella-specific neutralizing antibody titers.
作者信息
Lambert Nathaniel D, Pankratz V Shane, Larrabee Beth R, Ogee-Nwankwo Adaeze, Chen Min-hsin, Icenogle Joseph P, Poland Gregory A
机构信息
Mayo Vaccine Research Group, Mayo Clinic, Rochester, Minnesota, USA.
出版信息
Clin Vaccine Immunol. 2014 Mar;21(3):340-6. doi: 10.1128/CVI.00681-13. Epub 2014 Jan 3.
Abstract
Rubella remains a social and economic burden due to the high incidence of congenital rubella syndrome (CRS) in some countries. For this reason, an accurate and efficient high-throughput measure of antibody response to vaccination is an important tool. In order to measure rubella-specific neutralizing antibodies in a large cohort of vaccinated individuals, a high-throughput immunocolorimetric system was developed. Statistical interpolation models were applied to the resulting titers to refine quantitative estimates of neutralizing antibody titers relative to the assayed neutralizing antibody dilutions. This assay, including the statistical methods developed, can be used to assess the neutralizing humoral immune response to rubella virus and may be adaptable for assessing the response to other viral vaccines and infectious agents.
摘要
由于某些国家先天性风疹综合征（CRS）的高发病率，风疹仍然是一个社会和经济负担。因此，一种准确、高效的高通量疫苗接种抗体反应测量方法是一项重要工具。为了在大量接种疫苗的个体中测量风疹特异性中和抗体，开发了一种高通量免疫比色系统。将统计插值模型应用于所得滴度，以完善相对于所检测的中和抗体稀释度的中和抗体滴度的定量估计。该检测方法，包括所开发的统计方法，可用于评估对风疹病毒的中和体液免疫反应，并且可能适用于评估对其他病毒疫苗和感染因子的反应。
相似文献
1
High-throughput assay optimization and statistical interpolation of rubella-specific neutralizing antibody titers.
Clin Vaccine Immunol. 2014 Mar;21(3):340-6. doi: 10.1128/CVI.00681-13. Epub 2014 Jan 3.
2
A novel cell-based high throughput assay to determine neutralizing antibody titers against circulating strains of rubella virus.
J Virol Methods. 2018 Feb;252:86-93. doi: 10.1016/j.jviromet.2017.11.011. Epub 2017 Nov 27.
3
Rubella virus neutralizing antibody response after a third dose of measles-mumps-rubella vaccine in young adults.
Vaccine. 2018 Sep 11;36(38):5732-5737. doi: 10.1016/j.vaccine.2018.08.010. Epub 2018 Aug 11.
4
Characterization of humoral and cellular immunity to rubella vaccine in four distinct cohorts.
Immunol Res. 2014 Jan;58(1):1-8. doi: 10.1007/s12026-013-8475-y.
5
Polymorphisms in HLA-DPB1 are associated with differences in rubella virus-specific humoral immunity after vaccination.
J Infect Dis. 2015 Mar 15;211(6):898-905. doi: 10.1093/infdis/jiu553. Epub 2014 Oct 6.
6
Rubella virus-specific humoral immune responses and their interrelationships before and after a third dose of measles-mumps-rubella vaccine in women of childbearing age.
Vaccine. 2020 Jan 29;38(5):1249-1257. doi: 10.1016/j.vaccine.2019.11.004. Epub 2019 Nov 12.
7
Rubella specific cell-mediated and humoral immunity following vaccination in college students with low antibody titers.
Vaccine. 2015 Nov 9;33(45):6093-8. doi: 10.1016/j.vaccine.2015.06.113. Epub 2015 Aug 12.
8
A large observational study to concurrently assess persistence of measles specific B-cell and T-cell immunity in individuals following two doses of MMR vaccine.
Vaccine. 2011 Jun 15;29(27):4485-91. doi: 10.1016/j.vaccine.2011.04.037. Epub 2011 May 1.
9
Single nucleotide polymorphisms/haplotypes associated with multiple rubella-specific immune response outcomes post-MMR immunization in healthy children.
Immunogenetics. 2015 Oct;67(10):547-61. doi: 10.1007/s00251-015-0864-z. Epub 2015 Sep 2.
10
Validation of monoplex assays detecting antibodies against Corynebacterium diphtheriae and Clostridium tetani toxins, rubella virus and parvovirus B19 for incorporation into Multiplex Serology.
Methods. 2019 Apr 1;158:44-53. doi: 10.1016/j.ymeth.2019.01.013. Epub 2019 Jan 28.
引用本文的文献
1
Serosurveillance for Measles and Rubella.
Vaccines (Basel). 2024 Jul 22;12(7):816. doi: 10.3390/vaccines12070816.
2
Long-term Neutralizing Antibody Levels Against Measles and Rubella Viruses Among Adults With 3 Doses of Measles-Mumps-Rubella Vaccine.
Open Forum Infect Dis. 2024 Jan 3;11(1):ofad700. doi: 10.1093/ofid/ofad700. eCollection 2024 Jan.
3
Associations of adaptive immune cell subsets with measles, mumps, and Rubella-Specific immune response outcomes.
Heliyon. 2023 Nov 28;9(12):e22998. doi: 10.1016/j.heliyon.2023.e22998. eCollection 2023 Dec.
4
Transcriptional signatures associated with rubella virus-specific humoral immunity after a third dose of MMR vaccine in women of childbearing age.
Eur J Immunol. 2021 Jul;51(7):1824-1838. doi: 10.1002/eji.202049054. Epub 2021 Apr 19.
5
Comparative Antibody Responses to the Live-Attenuated and Recombinant Herpes Zoster Vaccines.
J Virol. 2021 May 24;95(12). doi: 10.1128/JVI.00240-21.
6
Durability of humoral immune responses to rubella following MMR vaccination.
Vaccine. 2020 Dec 3;38(51):8185-8193. doi: 10.1016/j.vaccine.2020.10.076. Epub 2020 Nov 12.
7
Measles and rubella IgG seroprevalence in persons 6 month-35 years of age, Mongolia, 2016.
Vaccine. 2020 May 27;38(26):4200-4208. doi: 10.1016/j.vaccine.2020.04.024. Epub 2020 May 4.
8
Rubella virus-specific humoral immune responses and their interrelationships before and after a third dose of measles-mumps-rubella vaccine in women of childbearing age.
Vaccine. 2020 Jan 29;38(5):1249-1257. doi: 10.1016/j.vaccine.2019.11.004. Epub 2019 Nov 12.
9
Seroprevalence and durability of rubella virus antibodies in a highly immunized population.
Vaccine. 2019 Jun 27;37(29):3876-3882. doi: 10.1016/j.vaccine.2019.05.049. Epub 2019 May 21.
10
Characterization of rubella-specific humoral immunity following two doses of MMR vaccine using proteome microarray technology.
PLoS One. 2017 Nov 16;12(11):e0188149. doi: 10.1371/journal.pone.0188149. eCollection 2017.
本文引用的文献
1
Investigation into low-level anti-rubella virus IgG results reported by commercial immunoassays.
Clin Vaccine Immunol. 2013 Feb;20(2):255-61. doi: 10.1128/CVI.00603-12. Epub 2012 Dec 19.
2
Global use of rubella vaccines, 1980-2009.
J Infect Dis. 2011 Sep 1;204 Suppl 2:S579-84. doi: 10.1093/infdis/jir447.
3
Human leukocyte antigen genotypes in the genetic control of adaptive immune responses to smallpox vaccine.
J Infect Dis. 2011 Jun 1;203(11):1546-55. doi: 10.1093/infdis/jir167.
4
A qualitative and quantitative comparison of two rubella virus-specific IgG antibody immunoassays.
Viral Immunol. 2010 Aug;23(4):353-7. doi: 10.1089/vim.2010.0026.
5
Extended LTA, TNF, LST1 and HLA gene haplotypes and their association with rubella vaccine-induced immunity.
PLoS One. 2010 Jul 27;5(7):e11806. doi: 10.1371/journal.pone.0011806.
6
SNP/haplotype associations in cytokine and cytokine receptor genes and immunity to rubella vaccine.
Immunogenetics. 2010 Apr;62(4):197-210. doi: 10.1007/s00251-010-0423-6. Epub 2010 Mar 10.
7
2'-5'-Oligoadenylate synthetase single-nucleotide polymorphisms and haplotypes are associated with variations in immune responses to rubella vaccine.
Hum Immunol. 2010 Apr;71(4):383-91. doi: 10.1016/j.humimm.2010.01.004. Epub 2010 Jan 31.
8
Polymorphisms in the vitamin A receptor and innate immunity genes influence the antibody response to rubella vaccination.
J Infect Dis. 2010 Jan 15;201(2):207-13. doi: 10.1086/649588.
9
Correlation between rubella antibody levels and cytokine measures of cell-mediated immunity.
Viral Immunol. 2009 Dec;22(6):451-6. doi: 10.1089/vim.2009.0068.
10
Rubella vaccine-induced cellular immunity: evidence of associations with polymorphisms in the Toll-like, vitamin A and D receptors, and innate immune response genes.
Hum Genet. 2010 Feb;127(2):207-21. doi: 10.1007/s00439-009-0763-1. Epub 2009 Nov 10.
Zotero 插件